Novartis, Mylan Settle Feud Over Generic Vivelle-Dot
By Amanda Bransford (November 21, 2011, 7:09 PM EST) -- Drugmakers Novartis AG and Mylan Inc. have settled patent litigation over Mylan's bid to produce a generic version of Novartis' estrogen therapy drug Vivelle-Dot, which will allow the generic to be manufactured, Mylan announced Monday.
Under the settlement, Novartis will drop its lawsuits in New York and Vermont against Mylan and Mylan will receive a patent license to begin selling its generic version of Vivelle-Dot beginning in December 2013, subject to the approval by the U.S. Department of Justice and the Federal Trade Commission, according to a statement from Mylan.
Other details of the settlement were not disclosed.
Vivelle-Dot is an...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!